PEP-3R
Triple GLP-1 / GIP / glucagon receptor agonist
PEP-3R is a triple receptor agonist acting on GLP-1, GIP, and glucagon pathways. Early-phase research reports pronounced fat-loss and metabolic effects that exceed single- and dual-agonist analogues.
- Half-life
- ~6 days
- Administration
- Subcutaneous injection
- Research status
- Phase III clinical trials
What it is
PEP-3R is a next-generation incretin mimetic under investigation. Unlike semaglutide or tirzepatide, it is a triple agonist — activating GLP-1, GIP, and glucagon receptors. That tri-agonist profile drives weight reduction through both appetite suppression and increased energy expenditure.
Research Interests
- Targets multiple pathways for stronger weight-management outcomes
- Suppresses appetite while simultaneously raising caloric burn
- May produce greater body-weight reductions than GLP-1 or dual agonists
- Shows potential across obesity and related metabolic conditions
Safety Profile (Documented in Research)
- GI effects (nausea, slowed digestion) are common during early use
- Glucagon receptor activation may elevate heart rate
- Monitor liver enzymes and cardiovascular markers in research settings
Researcher tips
Fits cutting or fat-loss protocols alongside resistance training and high protein intake
Hydration, electrolytes, and dietary fiber reduce GI distress during titration
Hold each step long enough to read the response before escalating
Where to source
Optimum Formula10% Off$83.99 – $209.99View Product